(CRI) Carter’s - Ratings and Ratios
Apparel, Footwear, Accessories, Home Gear, Bedding
CRI EPS (Earnings per Share)
CRI Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 49.4% |
| Value at Risk 5%th | 77.9% |
| Relative Tail Risk | -4.07% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.58 |
| Alpha | -51.48 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.442 |
| Beta | 1.285 |
| Beta Downside | 0.819 |
| Drawdowns 3y | |
|---|---|
| Max DD | 71.26% |
| Mean DD | 28.64% |
| Median DD | 22.00% |
Description: CRI Carter’s November 14, 2025
Carter’s, Inc. (NYSE:CRI) designs, sources, and markets a portfolio of children’s apparel and related products-including Carter’s, OshKosh B’gosh, Skip Hop, and several licensed lines-across three operating segments: U.S. Retail, U.S. Wholesale, and International.
The company’s core offerings span baby and toddler basics (bodysuits, sleepwear, dresses) and play-time apparel (denim, overalls, knit tops) under the Carter’s and OshKosh brands, while the Skip Hop brand supplies bags, bedding, and accessories. Sales are generated through a mix of wholesale partners (department stores, specialty chains), company-owned retail locations, and direct-to-consumer channels such as carters.com, oshkosh.com, skiphop.com, and a mobile app.
Key recent metrics: FY2023 net revenue reached approximately $4.3 billion, with comparable-sales growth of 5% YoY driven largely by a 15% surge in e-commerce sales. The business benefits from a relatively low-price elasticity segment, as infant apparel demand is historically resilient to macro-economic cycles, while overall U.S. consumer discretionary spending and birth-rate trends remain primary drivers of top-line performance.
For a deeper, data-driven look at Carter’s valuation and peer benchmarks, the ValueRay platform provides a concise, analytics-focused overview.
CRI Stock Overview
| Market Cap in USD | 1,167m |
| Sub-Industry | Apparel, Accessories & Luxury Goods |
| IPO / Inception | 2003-10-24 |
| Return 12m vs S&P 500 | -44.0% |
| Analyst Rating | 2.33 of 5 |
CRI Dividends
| Dividend Yield | 6.47% |
| Yield on Cost 5y | 2.95% |
| Yield CAGR 5y | 51.97% |
| Payout Consistency | 94.2% |
| Payout Ratio | 53.0% |
CRI Growth Ratios
| CAGR 3y | -20.88% |
| CAGR/Max DD Calmar Ratio | -0.29 |
| CAGR/Mean DD Pain Ratio | -0.73 |
| Current Volume | 656.3k |
| Average Volume | 1128.4k |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (88.9m TTM) > 0 and > 6% of Revenue (6% = 170.0m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA -7.95pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 22.31% (prev 20.67%; Δ 1.65pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 151.2m > Net Income 88.9m (YES >=105%, WARN >=100%) |
| Net Debt (495.5m) to EBITDA (201.2m) ratio: 2.46 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.26 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (35.4m) change vs 12m ago 0.40% (target <= -2.0% for YES) |
| Gross Margin 46.79% (prev 48.28%; Δ -1.49pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 116.9% (prev 119.5%; Δ -2.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.72 (EBITDA TTM 201.2m / Interest Expense TTM 31.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.79
| (A) 0.26 = (Total Current Assets 1.13b - Total Current Liabilities 501.7m) / Total Assets 2.47b |
| (B) 0.35 = Retained Earnings (Balance) 874.4m / Total Assets 2.47b |
| (C) 0.06 = EBIT TTM 146.3m / Avg Total Assets 2.42b |
| (D) 0.53 = Book Value of Equity 846.6m / Total Liabilities 1.60b |
| Total Rating: 3.79 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 51.72
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield 5.53% = 2.77 |
| 3. FCF Margin 3.25% = 0.81 |
| 4. Debt/Equity 0.79 = 2.20 |
| 5. Debt/Ebitda 2.46 = -0.89 |
| 6. ROIC - WACC (= 1.37)% = 1.72 |
| 7. RoE 10.39% = 0.87 |
| 8. Rev. Trend -26.06% = -1.95 |
| 9. EPS Trend -46.07% = -2.30 |
What is the price of CRI shares?
Over the past week, the price has changed by +2.43%, over one month by +4.14%, over three months by +24.68% and over the past year by -35.83%.
Is Carter’s a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CRI is around 29.11 USD . This means that CRI is currently overvalued and has a potential downside of -10.35%.
Is CRI a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 3
- Sell: 2
- Strong Sell: 1
What are the forecasts/targets for the CRI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.8 | -11.3% |
| Analysts Target Price | 28.8 | -11.3% |
| ValueRay Target Price | 32.1 | -1.3% |
CRI Fundamental Data Overview November 07, 2025
P/E Trailing = 13.0122
P/E Forward = 16.4474
P/S = 0.4119
P/B = 1.2629
P/EG = 1.81
Beta = 1.079
Revenue TTM = 2.83b USD
EBIT TTM = 146.3m USD
EBITDA TTM = 201.2m USD
Long Term Debt = 498.1m USD (from longTermDebt, last fiscal year)
Short Term Debt = 150.5m USD (from shortTermDebt, last quarter)
Debt = 679.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 495.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.66b USD (1.17b + Debt 679.7m - CCE 184.2m)
Interest Coverage Ratio = 4.72 (Ebit TTM 146.3m / Interest Expense TTM 31.0m)
FCF Yield = 5.53% (FCF TTM 92.0m / Enterprise Value 1.66b)
FCF Margin = 3.25% (FCF TTM 92.0m / Revenue TTM 2.83b)
Net Margin = 3.14% (Net Income TTM 88.9m / Revenue TTM 2.83b)
Gross Margin = 46.79% ((Revenue TTM 2.83b - Cost of Revenue TTM 1.51b) / Revenue TTM)
Gross Margin QoQ = 45.08% (prev 48.14%)
Tobins Q-Ratio = 0.67 (Enterprise Value 1.66b / Total Assets 2.47b)
Interest Expense / Debt = 1.06% (Interest Expense 7.17m / Debt 679.7m)
Taxrate = 21.85% (3.24m / 14.8m)
NOPAT = 114.4m (EBIT 146.3m * (1 - 21.85%))
Current Ratio = 2.26 (Total Current Assets 1.13b / Total Current Liabilities 501.7m)
Debt / Equity = 0.79 (Debt 679.7m / totalStockholderEquity, last quarter 864.6m)
Debt / EBITDA = 2.46 (Net Debt 495.5m / EBITDA 201.2m)
Debt / FCF = 5.39 (Net Debt 495.5m / FCF TTM 92.0m)
Total Stockholder Equity = 855.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.60% (Net Income 88.9m / Total Assets 2.47b)
RoE = 10.39% (Net Income TTM 88.9m / Total Stockholder Equity 855.1m)
RoCE = 10.81% (EBIT 146.3m / Capital Employed (Equity 855.1m + L.T.Debt 498.1m))
RoIC = 8.47% (NOPAT 114.4m / Invested Capital 1.35b)
WACC = 7.10% (E(1.17b)/V(1.85b) * Re(10.75%) + D(679.7m)/V(1.85b) * Rd(1.06%) * (1-Tc(0.22)))
Discount Rate = 10.75% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.77%
[DCF Debug] Terminal Value 65.81% ; FCFE base≈166.2m ; Y1≈142.1m ; Y5≈110.2m
Fair Price DCF = 36.65 (DCF Value 1.34b / Shares Outstanding 36.4m; 5y FCF grow -17.63% → 3.0% )
EPS Correlation: -46.07 | EPS CAGR: -33.69% | SUE: 0.11 | # QB: 0
Revenue Correlation: -26.06 | Revenue CAGR: -6.52% | SUE: -1.26 | # QB: 0
Additional Sources for CRI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle